CLGN - רווח נקי למניה (EPS TTM) CollPlant

The EPS TTM history on the GURU.Markets service demonstrates profit dynamics, where the current level is -9.43. CollPlant Biotechnologies (CLGN) is developing an exclusive plant-based collagen platform while avoiding price dumping. Growth is driven by the precision of regenerative technologies and licensing deals. High barriers to entry are ensured by genetic engineering patents and strict medical oversight.

For CollPlant Biotechnologies (CLGN), the rolling annual net income per share serves as an indicator of the monetization efficiency of its bioprinting technologies. This metric assesses the portion of profit attributable to a single security over the last 12 months. The calculation is based on the ratio of total income to the total number of shares outstanding. Positive momentum confirms the sustainability of the rhCollagen expansion model within regenerative medicine, while a negative trend signals risks under tight monetary policy.